Atara Biotherapeutics Announces Board and Executive Changes
Ticker: ATRA · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $8.25, $8.2499, $36.0 m, $7.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
Related Tickers: ATRA
TL;DR
Atara Bio shakes up board & exec pay. Big changes coming?
AI Summary
Atara Biotherapeutics, Inc. announced on September 3, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside adjustments to compensatory plans for key personnel.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- September 3, 2024 (date) — Date of earliest event reported
FAQ
Who departed from Atara Biotherapeutics' board or executive team?
The filing indicates the departure of certain officers and directors, though specific names are not detailed in the provided excerpt.
What is the primary reason for this 8-K filing?
The filing is a current report detailing the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements.
When was the earliest event reported in this filing?
The earliest event reported was on September 3, 2024.
What is Atara Biotherapeutics' principal executive office address?
The principal executive offices are located at 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California, 91320.
What is Atara Biotherapeutics' fiscal year end?
Atara Biotherapeutics' fiscal year ends on December 31.
Filing Stats: 1,193 words · 5 min read · ~4 pages · Grade level 10.8 · Accepted 2024-09-03 17:05:01
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Mar
- $8.25 — of Common Stock, at a purchase price of $8.25 per Share and $8.2499 per share underly
- $8.2499 — a purchase price of $8.25 per Share and $8.2499 per share underlying the Pre-Funded War
- $36.0 m — fering are expected to be approximately $36.0 million, before deducting estimated offer
- $7.5 million — ering at an aggregate purchase price of $7.5 million. The Company intends to use the net pro
Filing Documents
- d852765d8k.htm (8-K) — 32KB
- d852765dex41.htm (EX-4.1) — 66KB
- d852765dex51.htm (EX-5.1) — 15KB
- d852765dex991.htm (EX-99.1) — 165KB
- g852765dsp18.jpg (GRAPHIC) — 4KB
- 0001193125-24-212168.txt ( ) — 483KB
- atra-20240903.xsd (EX-101.SCH) — 3KB
- atra-20240903_lab.xml (EX-101.LAB) — 18KB
- atra-20240903_pre.xml (EX-101.PRE) — 11KB
- d852765d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATARA BIOTHERAPEUTICS, INC. Date: September 3, 2024 By: /s/ Eric Hyllengren Eric Hyllengren Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer)